News & Events

Symbiosis gains Approval for French Tax Credit

Recently Symbiosis Pharmaceutical Services applied for a CIR (Crédit d’Impôt de Recherche) tax accreditation from the Minister of higher Education and research in France for R&D work on behalf of French companies. Our request was favourably accepted and we are now approved until 2016.

The CIR tax accreditation has provided Symbiosis with a strong basis to working with French companies and allows eligible companies to benefit from significant tax relief (Crédit d’Impôt de Recherche) on R&D activities carried out by Symbiosis on their behalf. You can find a link to our approval on the French governments’ website here:

Symbiosis would like to expand its work with French companies, to assist in developing drug projects, for clinical trials and niche commercial markets. If you have any other questions or you would like to discuss any potential projects with an expert in the sterile drug manufacturing field then please send an email to or call 44 (0)1786 220 000.

We look forward to hearing from you soon.

Symbiosis Pharmaceutical Services is a world class specialist in the manufacturing of sterile injectable drugs for clinical trials and niche commercial marketed products. Our aim is to successfully reduce our clients’ drug development times.

Get In Touch.

By ticking the box and clicking “Submit” below, you consent to receiving thought leadership, industry news, and invitations by email or other electronic means, which Symbiosis Pharmaceutical Services believes may be of value to you, relevant to your work and tailored to your professional profile and interests. This may include promotional information on products, services and events provided or organised by Symbiosis Pharmaceutical Services. By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Symbiosis' processing of your personal data, including its transfer internationally and to third parties, in accordance with it's privacy policy.